Patients with COPD hospitalized due to COVID-19 in Spain: a comparison between the first and second wave.
COPD
COVID-19
First and second wave of infection
Primera y segunda ola de infección
Prognosis
SARS-CoV-2
Journal
Revista clinica espanola
ISSN: 2254-8874
Titre abrégé: Rev Clin Esp (Barc)
Pays: Spain
ID NLM: 101632437
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
10
10
2022
accepted:
28
02
2023
medline:
3
5
2023
pubmed:
8
4
2023
entrez:
7
4
2023
Statut:
ppublish
Résumé
This work aimed to compare the characteristics, progress, and prognosis of patients with COPD hospitalized due to COVID-19 in Spain in the first wave with those of the second wave. This is an observational study of patients hospitalized in Spain with a diagnosis of COPD included in the SEMI-COVID-19 registry. The medical history, symptoms, analytical and radiological results, treatment, and progress of patients with COPD hospitalized in the first wave (from March to June 2020) versus those hospitalized in the second wave (from July to December 2020) were compared. Factors associated with poor prognosis, defined as all-cause mortality and a composite endpoint that included mortality, high-flow oxygen therapy, mechanical ventilation, and ICU admission, were analyzed. Of the 21,642 patients in the SEMI-COVID-19 Registry, 6.9% were diagnosed with COPD: 1128 (6.8%) in WAVE1 and 374 (7.7%) in WAVE2 (p = 0.04). WAVE2 patients presented less dry cough, fever and dyspnea, hypoxemia (43% vs 36%, p < 0.05), and radiological condensation (46% vs 31%, p < 0.05) than WAVE1 patients. Mortality was lower in WAVE2 (35% vs 28.6%, p = 0.01). In the total sample, mortality and the composite outcome of poor prognosis were lower among patients who received inhalation therapy. Patients with COPD admitted to the hospital due to COVID-19 in the second wave had less respiratory failure and less radiological involvement as well as a better prognosis. These patients should receive bronchodilator treatment if there is no contraindication for it.
Identifiants
pubmed: 37028707
pii: S2254-8874(23)00049-8
doi: 10.1016/j.rceng.2023.04.002
pmc: PMC10074726
pii:
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
298-309Informations de copyright
Copyright © 2023 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved.
Références
Cardiovasc Res. 2020 Dec 1;116(14):2197-2206
pubmed: 33063089
EClinicalMedicine. 2021 Mar;33:100789
pubmed: 33758801
PLoS One. 2020 May 11;15(5):e0233147
pubmed: 32392262
Rev Clin Esp. 2020 Nov;220(8):480-494
pubmed: 33994573
Rev Clin Esp (Barc). 2020 Nov;220(8):526-529
pubmed: 32836322
J Infect. 2021 Apr;82(4):84-123
pubmed: 33152376
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Int J Infect Dis. 2021 Apr;105:374-376
pubmed: 33684560
Transbound Emerg Dis. 2021 Mar;68(2):213-215
pubmed: 32892500
Aging (Albany NY). 2020 Apr 8;12(7):6049-6057
pubmed: 32267833
J Cardiovasc Pharmacol Ther. 2021 Mar;26(2):114-118
pubmed: 33078623
Crit Care Explor. 2021 Feb 22;3(2):e0346
pubmed: 33634266
N Engl J Med. 2020 Jun 18;382(25):2431-2440
pubmed: 32356627
J Clin Med. 2021 May 24;10(11):
pubmed: 34073928
Transbound Emerg Dis. 2021 Nov;68(6):3103-3106
pubmed: 33621389
Int J Chron Obstruct Pulmon Dis. 2021 Jan 05;15:3433-3445
pubmed: 33447021
PLoS One. 2021 Mar 31;16(3):e0248029
pubmed: 33788866
Crit Care. 2021 Jan 4;25(1):3
pubmed: 33397421
J Clin Pharmacol. 2021 Oct;61(10):1286-1300
pubmed: 33908637
Int J Infect Dis. 2021 Jan;102:17-19
pubmed: 33038556